< 生产厂家价格 >

N-亚硝基新烟草碱

N-亚硝基新烟草碱名称

[ CAS 号 ]:
37620-20-5

[ 中文名 ]:
N-亚硝基新烟草碱

[ 英文名 ]:
N-nitrosoanabasine

[中文别名 ]:

(R,s)-n-亚硝基新烟草碱

[英文别名 ]:

3-(1-Nitrosopiperidin-2-yl)pyridine
1-nitro-pyrene
Pyrene,1-nitro
Nitropyrene,Mono-,Di-,Tri-Tetra,isomers
3-Nitropyrene
nitropyrene
1-nitropyrne
3-(1-Nitroso-2-piperidinyl)pyridine
N-nitrosoanabasine
1-nitroso-anabasine

N-亚硝基新烟草碱物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
380.2±35.0 °C at 760 mmHg

[ 分子式 ]:
C₁₀H₁₃N₃O

[ 分子量 ]:
191.230

[ 闪点 ]:
183.8±25.9 °C

[ 精确质量 ]:
191.105865

[ PSA ]:
45.56000

[ LogP ]:
0.49

[ 蒸汽压 ]:
0.0±0.8 mmHg at 25°C

[ 折射率 ]:
1.625

[ 储存条件 ]:
-20°C Freezer

N-亚硝基新烟草碱安全信息

[ 符号 ]:

GHS06

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301

[ 警示性声明 ]:
P301 + P310

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter

[ 危害码 (欧洲) ]:
T

[ 风险声明 (欧洲) ]:
25

[ 安全声明 (欧洲) ]:
45

[ 危险品运输编码 ]:
UN2810 6.1/PG 3

[ 海关编码 ]:
2933990090

N-亚硝基新烟草碱合成路线

详细合成路线

N-亚硝基新烟草碱上下游产品

N-亚硝基新烟草碱上游产品

N-亚硝基新烟草碱下游产品

N-亚硝基新烟草碱海关

[ 海关编码 ]: 2933990090

[ 中文概述 ]:
2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

N-亚硝基新烟草碱文献

Pancreatic endoplasmic reticulum kinase activation promotes medulloblastoma cell migration and invasion through induction of vascular endothelial growth factor A.

PLoS ONE 10(3) , e0120252, (2015)

Evidence is accumulating that activation of the pancreatic endoplasmic reticulum kinase (PERK) in response to endoplasmic reticulum (ER) stress adapts tumor cells to the tumor microenvironment and enh...

Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.

Drug Metab. Dispos. 43(2) , 182-9, (2014)

Evaluation of drug-drug interaction (DDI) involving circulating inhibitory metabolites of perpetrator drugs has recently drawn more attention from regulatory agencies and pharmaceutical companies. Her...

Disparities in child mortality trends: what is the evidence from disadvantaged states in India? the case of Orissa and Madhya Pradesh.

Int J Equity Health 12 , 45, (2013)

The Millennium Development Goals prompted renewed international efforts to reduce under-five mortality and measure national progress. However, scant evidence exists about the distribution of child mor...

更多文献